Management of Severe and Critical COVID-19 Infection with Immunotherapies

Following the reduction in mortality demonstrated by dexamethasone treatment in severe COVID-19, many targeted immunotherapies have been investigated. Thus far, inhibition of IL-6 and JAK pathways have the most robust data and have been granted Emergency Use Authorization for treatment of severe dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Athale, Janhavi, Gallagher, Jolie, Busch, Lindsay M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293954/
https://www.ncbi.nlm.nih.gov/pubmed/36328635
http://dx.doi.org/10.1016/j.idc.2022.07.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293954/
https://www.ncbi.nlm.nih.gov/pubmed/36328635
http://dx.doi.org/10.1016/j.idc.2022.07.002

Ejemplares similares